Symic Biomedical Inc-製薬・医療分野:企業M&A・提携分析

GlobalDataが発行した調査報告書(DATA8014307)
◆英語タイトル:Symic Biomedical Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8014307
◆発行会社(リサーチ会社):GlobalData
◆発行日:2017年11月22日
◆ページ数:27
◆レポート形式:英語 / PDF
◆納品方法:Eメール
◆調査対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。GlobalData社の概要及び新刊レポートはこちらでご確認いただけます。

【レポートの概要】

Summary
Symic Biomedical Inc (Symic Biomedical) is a biopharmaceutical company that develops library of compounds that target and protect the ECM (extracellular matrix) from illness or injury-related degradation. The company’s ECM specific compounds facilitate local application, which enhances its ability to reduce inflammation and scarring only at the site of injury. Its clinical programs comprise cardiovascular, osteoarthritis and dermal scarring, among others. The company also collaborates with various companies for the clinical development of its osteoarthritis program. Symic Biomedical is headquartered in Emeryville, California, the US.

Symic Biomedical Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Symic Biomedical Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
Symic Biomedical Inc, Medical Devices Deals, 2011 to YTD 2017 9
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deal Details 11
Venture Financing 11
Symic Biomedical Raises USD30 Million in Series B Venture Financing 11
Symic Biomedical Raises USD25 Million in Series A-2 Financing 12
Symic Biomedical Raises USD15 Million in Series A Financing 13
Symic Biomedical Raises USD0.53 Million in Extended Venture Financing 14
Symic Biomedical Raises US$0.8 Million In Venture Financing 15
Partnerships 16
Symic Biomedical Enters into Co-Development Agreement with Nordic Bioscience 16
Symic Biomedical Inc – Key Competitors 17
Symic Biomedical Inc – Key Employees 18
Symic Biomedical Inc – Locations And Subsidiaries 19
Head Office 19
Other Locations & Subsidiaries 19
Recent Developments 20
Corporate Communications 20
Jan 30, 2017: Symic Bio Appoints Scott W. Morrison to Board of Directors 20
Jan 07, 2016: Symic Appoints Rinko Ghosh President and Chief Business Officer 21
Product News 22
11/10/2016: Symic Bio and Nordic Bioscience Complete Enrollment of MODIFY-OA Trial of SB-061 for the Treatment of Osteoarthritis 22
05/18/2017: Symic Bio Announces Results from MODIFY-OA Trial of SB-061 for the Treatment of Osteoarthritis of the Knee 23
02/24/2017: Symic Bio Announces Last Patient Enrolled in SHIELD Trial of SB-030 for Interventions in Peripheral Artery Disease 24
Clinical Trials 25
Aug 23, 2017: Symic Bio Enrolls First Patient in MODIFY2 Phase 2 Trial of SB-061 for the Treatment of Osteoarthritis 25
Jun 13, 2016: Symic Advances Product Candidate SB-061 into Clinical Development for the Treatment of Osteoarthritis 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List of Tables
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Key Facts 2
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
Symic Biomedical Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
Symic Biomedical Inc, Deals By Therapy Area, 2011 to YTD 2017 8
Symic Biomedical Inc, Medical Devices Deals, 2011 to YTD 2017 9
Symic Biomedical Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Symic Biomedical Raises USD30 Million in Series B Venture Financing 11
Symic Biomedical Raises USD25 Million in Series A-2 Financing 12
Symic Biomedical Raises USD15 Million in Series A Financing 13
Symic Biomedical Raises USD0.53 Million in Extended Venture Financing 14
Symic Biomedical Raises US$0.8 Million In Venture Financing 15
Symic Biomedical Enters into Co-Development Agreement with Nordic Bioscience 16
Symic Biomedical Inc, Key Competitors 17
Symic Biomedical Inc, Key Employees 18
Symic Biomedical Inc, Other Locations 19

【免責事項】
http://www.globalresearch.jp/disclaimer

★リサーチレポート[ Symic Biomedical Inc-製薬・医療分野:企業M&A・提携分析(Symic Biomedical Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile)]についてメールでお問い合わせはこちらでお願いします。

◆H&Iグローバルリサーチのお客様(例)◆